Aydoğdu, SelimeMergen, AzizeAksoy, BaşakAkbay, Hazal S.Cipe, FundaDikme, GürcanBozkurt, CeyhunFışgın, Tunç2021-05-152021-05-1520190268-33691476-5365https://hdl.handle.net/20.500.12939/33045th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT) -- MAR 24-27, 2019 -- Frankfurt, GERMANYAllogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.eninfo:eu-repo/semantics/closedAccessDonorsAllogeneic Stem CellPediatricsConference Object54196196WOS:000487707800216Q1